Zacks Investment Research Lowers Scpharmaceuticals (NASDAQ:SCPH) to Hold

Zacks Investment Research cut shares of Scpharmaceuticals (NASDAQ:SCPH) from a buy rating to a hold rating in a research note released on Thursday, reports.

According to Zacks, “scPharmaceuticals, Inc., is a biopharmaceutical company. It engaged in developing pharmaceutical products for subcutaneous delivery. The Company’s pipeline programs include: scFurosemide lead product candidate, Furoscix, consists of its proprietary subcutaneous formulation of furosemide delivered via sc2Wear Infusor for diuresis in heart failure patients outside of the acute care setting. scPharmaceuticals, Inc., is based in BURLINGTON, United States. “

Separately, ValuEngine downgraded Scpharmaceuticals from a buy rating to a hold rating in a report on Tuesday.

SCPH traded up $0.03 during trading on Thursday, hitting $5.70. 9,700 shares of the stock were exchanged, compared to its average volume of 61,280. The stock has a 50 day moving average price of $4.37. The firm has a market capitalization of $95.69 million, a price-to-earnings ratio of -3.58 and a beta of 0.94. Scpharmaceuticals has a 1 year low of $2.44 and a 1 year high of $6.40. The company has a debt-to-equity ratio of 0.10, a quick ratio of 8.50 and a current ratio of 8.50.

Scpharmaceuticals (NASDAQ:SCPH) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.10. As a group, equities analysts forecast that Scpharmaceuticals will post -2.02 EPS for the current year.

A hedge fund recently bought a new stake in Scpharmaceuticals stock. SG Americas Securities LLC acquired a new position in shares of Scpharmaceuticals Inc (NASDAQ:SCPH) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 16,993 shares of the company’s stock, valued at approximately $51,000. SG Americas Securities LLC owned 0.09% of Scpharmaceuticals as of its most recent SEC filing. 40.26% of the stock is owned by institutional investors and hedge funds.

About Scpharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

See Also: Dividend

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with's FREE daily email newsletter.